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ABSTRACT 
Purpose: To investigate the effects of a natural oil-based emulsion containing allantoin 
versus aqueous cream for preventing and managing radiation induced skin reactions (RISR). 
Methods and Materials: A total of 174 patients were randomised and participated in the 
study. Patients either received Cream 1 (the natural oil-based emulsion containing allantoin) 
or Cream 2 (aqueous cream). Skin toxicity, pain, itching and skin-related quality of life 
scores were collected for up to four weeks after radiation treatment. 
Results: Patients who received Cream 1 had a significantly lower average level of Common 
Toxicity Criteria at week 3 (p<0.05), but had statistically higher average levels of skin 
toxicity at weeks 7, 8 and 9 (all p<0.001). Similar results were observed when skin toxicity 
was analysed by grades. With regards to pain, patients in the Cream 2 group had a 
significantly higher average level of worst pain (p<0.05) and itching (p=0.046) compared to 
the Cream 1 group at week 3, however these differences were not observed at other weeks. 
In addition, there was a strong trend for Cream 2 to reduce the incidence of grade 2 or more 
skin toxicity in comparison to Cream 1 (p=0.056). Overall, more participants in the Cream 1 
group were required to use another topical treatment at weeks 8 (p=0.049) and 9 (p=0.01). 
Conclusion: The natural oil-based emulsion containing allantoin appears to have similar 
effects for managing skin toxicity compared to aqueous cream up to week 5, however, it 
becomes significantly less effective at later weeks into the radiation treatment and beyond 
treatment completion (week 6 and beyond). There were no major differences in pain, itching 
and skin-related quality of life. In light of these results, clinicians and patients can base their 
decision on costs and preferences. Overall, aqueous cream appears to be a more preferred 
option.  
 
 
 
 
*BLINDED Revised Manuscript (Unmarked)
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INTRODUCTION 
Radiotherapy remains an essential treatment for patients with cancer and is 
associated with a number of short term and long term side effects (1). One of these side 
effects includes radiation-induced skin reactions (RISR), also known as radiation dermatitis, 
which affects up to 90% of cancer patients receiving radiotherapy (2-4). The reactions are 
the combined result of a decrease in functional stem cells, changes in the skin’s endothelial 
cells, inflammation, and skin cell necrosis (5). Radiation-induced skin reactions are often 
characterised by oedema, erythema, changes in pigmentation, fibrosis and ulceration (6, 7). 
Signs and symptoms may include skin dryness, itching discomfort, pain, warmth, and 
burning (7, 8). Radiation-induced skin reactions have an impact on pain and quality of life 
in this patient group (9), and if severe, may necessitate changes to the radiation schedule for 
the patient (10).  
The development of RISR may begin immediately, with increasing toxicity 
occurring at 2-3 weeks, with effects accumulating across the course of treatment, and may 
persist up to 4 weeks after treatment ends (4). Risk factors influencing RISR could include 
age, general health, ethnic origin, co-existing diseases, ultraviolet exposure, hormonal 
status, genetic factors, treatment dose, volume, and number of fractions of radiation, radio-
sensitizers, concurrent chemotherapy and the site of treatment (7, 11, 12). A range of 
interventions are used for prophylaxis and management of these reactions. These 
interventions include: (i) topical preparations (both steroidal and non-steroidal), (ii) 
dressings, (iii) systemic treatment such as amifostine, oral hydrolytic enzymes, 
pentoxifylline and zinc supplement, and (iv) alternating modes of radiation delivery. A 
recent overview of systematic reviews and a systematic review of randomised controlled 
trials conducted by our team concluded that the use of these interventions are not yet 
supported by conclusive evidence, and therefore warrant further investigations (10, 13).  
Topical interventions are the most accessible form of treatment. A recently 
developed natural oil-based emulsion containing allantoin (NOCA) is an Australian owned 
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product that comprises allantoin, purified water, sweet almond oil, olive oil, rice bran oil, 
emulsifying wax, milk protein, aloe vera, vitamin E, glycerol caprylate, piroctone alamine 
and guarsilk. Anecdotal reports by patients experiencing RISR and radiation oncologists in 
a number of Australian cancer centres suggest that this emulsion may be effective in 
promoting healing, comfort, and pain relief. This product is used in some Australian and 
New Zealand cancer centres in the management of RISR, however there has not been 
empirical evidence supporting this claim. This study investigated the effects of the NOCA 
compared to aqueous cream (which is the current standard of care at the study site) in 
patients with breast cancer/ lung cancer and head and neck cancer receiving radical 
radiotherapy. 
 
METHODS AND MATERIALS 
Participants in this double-blind randomised controlled trial were selected from patients 
receiving radical radiotherapy for lung, breast or head and neck cancer at the Royal 
Brisbane and Women’s Hospital, a tertiary cancer care centre. All eligible patients were 
approached consecutively during Oct 2012 to April 2013. Patients over 18 years of age with 
definitive diagnosis of breast, lung and head and neck cancer, receiving radiotherapy (>50 
Gy) either as primary treatment or post-operative treatment to their chest, breast/axilla or 
head and neck were eligible. Patients were excluded if they were unable to consent or had a 
pre-existing skin rash, ulceration or open wound in the treatment area. Patients were also 
excluded if they had a known skin allergy or other systemic skin disease (even if not 
directly affecting irradiated fields), any known allergic reaction to any ingredient of either 
the NOCA or the aqueous cream, failed patch test, or were not available for follow-up post-
treatment. Eligible and consented patients were recruited into the study. Ethics was 
approved before commencement of the study by the Royal Brisbane and Women’s Hospital 
Human Research Ethics Committee (HREC/12/QBRW/90). Baseline characteristics were 
collected and clinical variables such as age, gender, ethnicity, stage of cancer, comorbidity, 
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prior and concurrent anti-cancer therapy, body mass index, smoking, cup-size (for patients 
with breast and axilla treated), daily dose (Gy/fraction), total dose to region of interest, 
radiation technique (external beam via Tomotherapy or 3D conformal RT) and boost 
treatment were recorded.  
 
Patients were randomly allocated (1:1) to the intervention group to receive Cream 1 
(NOCA), or Cream 2 (aqueous cream). Blocked randomisation was performed, with a block 
size of six, by a computer generated random number list prepared by an investigator who 
had no clinical involvement in the trial. This process concealed the sequence until 
interventions were assigned. Stratification by irradiated site: (1) breast, (2) lung or (3) head 
and neck, BMI categories: (1) underweight <18.50, (2) normal =18.50-24.99, (3) 
overweight =25-29.99, or (4) obese >30 and smoking status: (1) smoking, or (2) non-
smoking defined the 24 strata. After patient consent was obtained, the research nurse then 
randomised participants to either receive Cream 1, or receive Cream 2 according to the 
generated blocking sequence. Blinding was accomplished by not disclosing to the research 
nurse, medical officers, radiation therapists, nurses or participants which preparation was 
used. Both topical preparations (Cream 1 and Cream 2) were white in colour, had similar 
consistency, and did not have a distinct odour. Both topical preparations were provided and 
coded as Cream 1 or Cream 2 by the manufacturer in identical tube containers. The 
manufacturer only disclosed the cream coded at the completion of data collection. 
Patients were instructed to commence applying a thin layer of their allocated cream 
on the area of skin being irradiated at the onset of radiotherapy, twice a day or more as 
needed depending on the occurrence of RISR and pain, until the skin reaction subsided. The 
protocol did not specify the time of day for cream application. If moist desquamation 
occurred, the topical preparation was discontinued in the area of skin breakdown and 
dressings were applied until the wound healed as per standard care. Patients were asked to 
continue to apply the topical preparation onto the irradiated area that displayed no 
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breakdown. All participants were given written instructions on how to apply the allocated 
treatment (see Appendix 1). All other skin care advice given to both groups of patients were 
the same, as per the local policy of the Royal Brisbane and Women’s Hospital (see 
Appendix 2). Baseline and weekly scores during treatment were collected when patients 
attended the radiation oncology department. At completion of radiotherapy, the research 
nurse contacted the patient via telephone over the four weeks post-treatment. Data 
collection was undertaken on the same day as much as possible, however, this was not 
always possible due to logistical challenges. 
Severity of RISR was the primary outcome and was measured using The Common 
Toxicity Criteria for Adverse Events (CTCAE- Version 4.0) (14). This instrument is 
commonly used and well validated in radiation oncology for assessing radiation dermatitis 
(15). The assessment was undertaken on the worst toxicity present within the treatment field 
by a research nurse with extensive clinical experience in radiation oncology during their 
review. We assessed the inter-rater reliability by randomly examining the independent 
assessments of skin toxicity scores for 20 patients, evaluated by the nurse and the treating 
medical staff during the last week of treatment. The intra-class correlation coefficient was 
one, representing absolute agreement. The secondary outcomes were skin-related quality of 
life, pain, itching, and other cream usage. Skindex-16 was used to measure the effects of 
skin condition on quality of life (16, 17). This tool is a reliable and valid self-administered 
survey comprising 16 items in three scales to assess patient emotion, symptoms and 
functioning. Item responses are standardized from 0 (no effect) to 100 (maximal effect). 
Permission to use this tool was granted by the author. We also measured pain using the 
worst pain item of the Brief Pain Inventory (BPI) from the preceding seven days (18). The 
participant was asked to rate their pain level at the irradiated area. The BPI was selected 
because it was an easy tool to assess pain and has been well validated in both the clinical 
and research settings in cancer care. The scale of 0 to 10 is simple for patients to use and 
reflects common clinical assessment of pain. We considered 1-3 as mild pain, 4-6 as 
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moderate pain and 7-10 as severe pain. Itching was scored on a numeric analogue scale of 
0-10 in the treated skin (0= no itching at all), (10= itching as bad as you can imagine). We 
considered 1-3 as mild itching, 4-6 as moderate itching and 7-10 as severe itching. 
Treatment interruptions due to severe skin reactions were documented throughout the study 
(Yes/No). This decision was determined by the treating radiation oncologist. Adverse events 
included any allergic reactions from the allocated treatment, and were reported by 
investigators using the CTCAE v4 (14). In addition, trial treatment compliance and use of 
other topical treatment was also documented. 
A sample size of at least 81 in each arm was required to detect a 20% difference in 
Grade 2 or more skin reactions using a 2-sided significance test (α=0.05) with a power of 
80%. A 20% difference was considered clinically significant. Assuming that approximately 
5% of patients could drop out of the study; an additional 5 patients in each arm were added 
in the final sample size. 
Intention-to-treat analyses were carried out. Patient characteristics between arms 
were compared using the chi-square test for discrete variables and the t-test for continuous 
variables. Acute reactions were evaluated using Kaplan-Meier actuarial plots (time-to-event 
curves) with the log-rank test used to determine significant difference between arms. The 
proportion of patients exhibiting a specified toxicity at a given time were plotted as 
prevalence plots, with 95% confidence intervals to show severity and duration of reactions. 
Univariate logistic regression models were used to determine the significance of factors 
(α≤0.05) to be included in the multivariate logistic regression model. A generalized linear 
interactive modelling package (GLIM4) was used to analyse the data. 
 
RESULTS 
A total of 174 patients were randomised and completed planned radiation therapy 
and assessment. Eighty-nine participants received Cream 1 and 85 received Cream 2. 
Participant and treatment characteristics are listed in Table 1. All patients completed 
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radiation treatment as planned excepted for one patient in the Cream 1 group (See Fig 1). 
There was no statistically significant difference in participants’ characteristics when 
considering age, gender, ethnicity, treatment site, smoking status, body mass index, breast 
cup size (only for breast cancer patients), concurrent anti-cancer therapy, dose (Gy), 
fractions and boost application.  
 
Insert Table 1 and Figure 1 about here 
 
CTCAE Skin Toxicity 
Overall, patients who received Cream 1 had a significantly lower average level of skin 
toxicity at week 3 (p<0.05), but had statistically higher average levels of skin toxicity at 
weeks 7, 8, and 9 (all p<0.001) (see Fig 2). When investigating skin toxicity by grades, 
there was a significantly higher proportion of patients developing Grade 1 or more skin 
toxicity in patients receiving Cream 2 at week 3 (p=0.02). However, there were significantly 
higher proportions of patients developing Grade 1 or more skin toxicity in patients receiving 
Cream 1 at weeks 6 (p=0.048) and 8 (p=0.009). There were higher proportions of patients 
developing Grade 2 or more skin toxicity in the Cream 1 group compared to the Cream 2 
group at weeks 6 (p=0.045), 7 (p<0.001), 8 (p=0.02) and 9 (p=0.001) (See Fig 3). There 
were no significant differences in the time-to-event data when examining the incidence of 
Grade 2 or more skin toxicity (p=0.82) (see Suppl 3) and Grade 3 or more skin toxicity 
(p=0.85) (see Suppl 4). There was no association between cup size (A,B,C vs D, E, F and 
G) and incidence of Grade 2 or more skin toxicity (p=0.63) in the sub-group analysis of 
patients having their breast or axilla treated (n=89). 
 
Insert Figures 2 and 3 about here 
 
Pain, itching, skin-related quality of life and other cream usage 
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In regards to pain measured as worst pain over the past 7 days ranging from 0-10, 
patients in the Cream 2 group had a significantly higher average level of worst pain 
compared to the Cream 1 group at week 3 (p<0.05), but not at other weeks (see Suppl 5). 
Similarly, when we examined worst pain by severity, a significantly higher proportion of 
patients in the Cream 2 group experienced (moderate or more) worst pain compared to the 
Cream 1 group at week 3 (p=0.03). However, at later weeks, higher percentages of patients 
in the Cream 1 group developed (severe) worst pain at week 4 (p=0.04), and (weak or more) 
worst pain at week 6 (p=0.04) and week 7 (p<0.001). 
 
In terms of itching, patients in the Cream 2 group had a significantly higher level of 
itching compared to those in the Cream 1 group at week 3 (p<0.05). However, when the 
severity of itching was examined (moderate or more), we did not observe any difference. 
There were no differences in skin-related quality of life scores at any week with all p>0.05 
and in participants’ need for any dressing (p=0.45) throughout all time points between 
groups. There were no adverse effects reported in either group. However, a significantly 
higher proportion of participants in the Cream 1 group used a range of other topical 
treatments in addition to the allocated cream to manage their skin toxicity other than the 
trial cream at weeks 8 (p=0.049) and 9 (p=0.01) (see Suppl 6). 
 
 Among those who developed skin toxicity as measured by CTCAE Grade 2 or more 
(n=148), there was no difference in pain and itching between the Cream 1 group and the 
Cream 2 group with all p>0.05. Among those who developed CTCAE Grade 3 or more 
(n=27), there was a significant difference in mild itching, but not in any other categories of 
itching or pain (see Table 2). 
 
Insert Table 2 about here. 
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Univariate and multivariate Analysis  
A logistic regression model examined the association between factors (including 
treatment arm and demographic/clinical characteristics) and the binary dependent variable 
(CTCAE Grade 2 or more) skin toxicity. At the univariate level, skin toxicity was associated 
with age (p=0.04), treatment site (breast vs lung) (p<0.001), and boost application 
(p<0.001). These variables were subsequently fitted to the multivariate regression model. 
The treatment site (lung) was found to be a significant independent predictive factor for 
Grade 2 or more skin toxicity (p<0.001) (See Table 3). There was a strong trend for Cream 
2 to reduce the incidence of grade 2 or more skin toxicity in comparison to Cream 1 
(p=0.056). 
 
Insert Table 3 about here 
 
DISCUSSION 
Over the years, there have been technologic advances in radiation treatment (19, 20), 
however skin reactions remain a prevalent issue facing this patient population. The results 
of this study suggest that over half of all participants developed Grade 2 or more skin 
toxicity and approximately 16% of participants developed a Grade 3 skin toxicity sometime 
during their treatment. A systematic review undertaken by our team suggested that the most 
potentially effective treatment may be systemic oral enzymes and that no single treatment is 
superior to other treatments in preventing and managing radiation skin reactions (10). 
Despite this, topical treatments remain a key area of skin care practice, with the literature 
reporting a range of products being used around the world (10, 21). 
This study was originally designed due to anecdotal reports from patients and 
healthcare professionals suggesting the potential efficacy of the NOCA. The results of our 
study indicate that this oil-based natural emollient is not superior to the usual practice 
(aqueous cream) in our cancer care centre. The results of this study report that the outcomes 
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of both topical interventions are quite similar. The NOCA appears to be more effective 
(though not significantly) for managing skin toxicity compared to aqueous cream up to 
week 5, however, it becomes less effective at later weeks into the treatment and beyond 
radiation treatment completion (week 6 and beyond). This group of patients also used more 
topical treatment other than the allocated treatment. However, there were no major 
differences in pain, itching and skin-related quality of life between the two groups. In light 
of these results, clinicians and patients can base their decision on costs and preferences. We 
are hesitant to recommend the use of both creams during radiation treatment (i.e. the NOCA 
from week 0 to week 5, then the aqueous cream thereafter). Because this approach is not yet 
tested and can be confusing to patients especially if they develop Grade 2 or more skin 
toxicity and requiring dressings. 
There have been recent clinical studies suggesting the potential detrimental effects 
of aqueous cream on healthy individuals (22) or those with previous history of atopic 
dermatitis (23). There has also been a suggestion that aqueous cream contains sodium lauryl 
sulphate and has not been designed to be a leave-on emollient, therefore should not be used 
for managing RISR (24). To the best of our knowledge, there has been no randomised 
controlled trial reporting detrimental effects for patients experiencing RISR. Despite these 
concerns, a recent UK survey study also confirmed that aqueous cream is a popular choice 
for treating RISR (21). Aqueous cream is commonly used possibly because of its potential 
benefits and low cost. The result of this study favouring aqueous cream is consistent with 
findings from our previous RCT. In 2002, a Phase III non-blinded RCT conducted by our 
research team reported that aqueous cream was more useful for reducing dry desquamation 
and pain related RISR compared to aloe vera gel (25). A recent RCT conducted in 2013 
suggested no difference in outcomes between those who received calendula cream and 
aqueous cream for managing RISR (26). The current study reports that aqueous cream is 
superior to the NOCA in terms of severity of skin toxicity at least at certain weeks. Given 
the positive results of aqueous cream in comparison with an emollient, it is reasonable to 
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speculate that the barrier function of the paraffin oil in the aqueous cream might be 
advantageous for patients with RISR. Given a number of barrier topical interventions are 
now available, future trials can investigate the results across different types of barrier 
treatments for managing RISR.  
In this study, we were not able to measure skin dose, which is a limitation of this 
study. In spite of this, we are confident of our results. Overall, this is a suitably powered, 
rigorously designed randomised controlled trial. The two groups were extremely well 
balanced and comparable based on the similar demographic and clinical/treatment 
characteristics listed in Table 1. These findings indicate a successful stratified and blocked 
randomisation. In addition, the intra-class correlation coefficient of “1” suggested high 
inter-rater reliability of the trial. Due to ethical concerns of limiting patients to use other 
skin treatments, the study design allowed the use of other topical treatment as prescribed by 
their medical officers. Despite this, we have conducted intention-to-treat analysis. We 
believe that the finding that one group had to use significantly more of other cream was a 
significant finding in itself. 
 Despite the high number of randomised controlled trials in the management of RISR, 
the evidence base is limited with a very low number of studies investigating the same 
interventions (10). This study adds to the literature to inform health professionals and 
patients of the efficacy of a NOCA commonly used in Australian cancer care centres in 
comparison to another commonly used topical intervention in patients experiencing RISR. 
Future research should continue to identify the best topical regimen for this important 
clinical problem. 
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Table 1. Participant and treatment characteristics between group (n=174) 
 
 Cream 1 
(NOCA) 
N=89 
Cream 2 
 (Aqueous cream) 
N=85 
 
 
p-value 
Age M=60.03 (SD=13.51) M=60.74 (SD=11.94) 0.72 
Gender 
M 
F 
 
30 (33.7%) 
59 (66.3%) 
 
32 (37.6%) 
53 (62.4%) 
 
 
0.59 
Ethnicity 
Caucasian 
Other 
 
86 (96.6%) 
3 (3.4%) 
 
80 (94.1%) 
5 (5.9%) 
 
 
0.43 
Treatment site 
Breast and axilla 
Lung 
Head and Neck 
 
45 (50.6%) 
11 (12.4%) 
33 (37.1%) 
 
44 (51.8%) 
9 (10.6%) 
32 37.6 %) 
 
 
 
0.94 
Charlson Comorbidity Index  M=.54 (SD=.92) M=.38 (SD=.76) 0.20 
Smoking 
Yes 
No 
 
76 (85.4%) 
13 (14.6%) 
 
77 (90.6%) 
8 (9.4%) 
 
 
0.29 
Body Mass Index 
Underweight (<18.5) 
Normal (18.5-24.99) 
Overweight (25.0-29.9) 
Obese (>30) 
 
1 (1.1%) 
32 (36%) 
28 (31.5%) 
28 (31.5%) 
 
1 (1.2%) 
27 (31.8%) 
26 (30.6%) 
31 (36.5%) 
 
 
 
 
0.91 
Breast Cup Size  
(only for breast and axilla) 
A 
B 
C 
D 
E, F and G 
 
 
17 (37.7%) 
7 (15.6%) 
8 (17.8%) 
7 (15.6%) 
6 (13.3%) 
 
 
12 (27.3%) 
5 (11.4%) 
7 (15.9%) 
11 (25%)  
9 (20.4%) 
 
 
 
 
 
 
0.60 
Concurrent anticancer therapy 
Chemotherapy 
Biotherapy (including MABs) 
Hormonal therapy 
 
20 (22.5%) 
8 (9.0%) 
13 (14.6%) 
 
19 (22.4%) 
2 (2.4%) 
16 (18.8%) 
 
 
 
0.15 
Treatment Technique 
3D Conformal RT 
Tomotherapy 
 
59 (66.3%) 
30 (33.7%) 
 
64 (75%) 
21 (24.7%) 
 
 
0.18 
Dose (Gy) M=61.69 (SD=6.22) M=60.53 (SD=6.11) 0.22 
Fractions M=30.08 (SD=3.47) M=29.11 (SD=3.96) 0.09 
Boost Applied 54 (60.7%) 50 (58.8%) 0.80 
Note. M=Mean, SD=Standard Deviation, NOCA = Natural oil-based emulsion containing 
allantoin 
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Table 2. Number of participants developing pain and itching (by severity) in those who 
developed CTCAE Grade 2 or more and Grade 3 or more 
 
CTCAE Skin Toxicity (Grade 2 or more) (148/174) 53% 
 Cream 1 
(NOCA) 
Cream 2 
(Aqeuous Cream) 
 
 Subject at 
risk 
Percentage Subject at 
risk 
Percentage p values 
CTCAE  
Skin Toxicity 
(Grade 2 or more) 
79/148 53% 69/148 47% 0.25 
Pain* 
Mild 
Moderate 
Severe 
 
35/79 
26/79 
12/79 
 
44% 
33% 
15% 
 
32/69 
17/69 
20/69 
 
46 
25 
29 
 
0.81 
0.27 
0.40 
Itching* 
Mild 
Moderate 
Severe 
 
41/79 
26/79 
12/79 
 
52% 
33% 
15% 
 
35/69 
20/69 
14/69 
 
51 
29 
20 
 
0.89 
0.06 
0.42 
CTCAE Skin Toxicity (Grade 3 or more) (27/174) 16% 
 Cream 1 
(NOCA) 
Cream 2 
(Aqeuous Cream) 
 
 Subject at 
risk 
Percentage Subject at 
risk 
Percentage p values 
CTCAE 
Skin Toxicity 
(Grade 3 or more) 
15/27 56% 12/27 44% 0.41 
Pain* 
Mild 
Moderate 
Severe 
 
5/15 
4/15 
6/15 
 
33% 
27% 
40% 
 
1/12 
3/12 
8/12 
 
8% 
25% 
66% 
 
0.12 
0.92 
0.17 
Itching* 
Mild 
Moderate 
Severe 
 
6/15 
6/15 
3/15 
 
40% 
40% 
20% 
 
0/12 
6/12 
6/12 
 
0% 
50% 
50% 
 
0.01** 
0.60 
0.10 
Note. * Mild = >1/10, Moderate= >4/10, Severe, >7/10. **p<0.01. 
NOCA = Natural oil-based emulsion containing allantoin 
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Table 3. Logistic regression model: Factors associated with CTCAE Skin Toxicity 
(Grade 2 or more)  
  
 
Hazard 95% CI 
Lower  
95% CI 
Upper 
p value 
Univariate Model     
Intervention Arm     
NOCA vs Aqueous 0.55 0.23 1.28 0.16 
Age 0.97 0.93 1.00 0.04* 
Gender     
Male vs Female 1.39 0.60 3.26 0.44 
Technique     
Tomotherapy vs 3D Conformal  0.68 0.26 1.81 0.44 
BMI      
Normal vs Overweight 0.69 0.25 1.90 0.47 
             vs Obese  1.17 0.39 3.44 0.78 
                         vs Underweight 0.16 0.01 2.77 0.20 
Treatment Site       
Breast vs Lung 0.04 0.01 0.13 <0.001** 
           vs H&N 1.02 0.31 3.38 0.97 
Chemotherapy     
No vs Yes 0.48 0.20 1.18 0.11 
Biotherapy     
No vs Yes 0.86 0.17 4.33 0.86 
Smoking     
No vs Yes 0.71 0.22 2.32 0.58 
Dose 1.04 0.97 1.11 0.23 
Boost     
No vs Yes 5.16 2.04 13.07 <0.001** 
     
Multivariate Model     
Intervention arm     
NOCA vs aqueous 0.34 0.11 1.03 0.056 
Age 1.00 0.95 1.04 0.84 
Treatment site     
Breast vs Lung 0.06 0.01 0.30 <0.001** 
           vs H&N 1.57 0.39 6.30 0.53 
Boost     
No vs Yes 2.28 0.61 8.60 0.22 
Note. *p< 0.05 **p<0.001. NOCA = Natural oil-based emulsion containing allantoin 
Figure 1. CONSORT Participant Flow Diagram
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Figure 2. CTCAE Skin Toxicity (0-4) between group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of subjects 
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Figure 3. CTCAE Skin Toxicity (2 or more) between group  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Week 1 2 3 4 5 6 7 8 9 10 11 
Cream 1 7/89 4/89 18/89 36/89 57/89 64/89 63/88 35/87 22/85 5/62 0/19 
Cream 2 0/85 7/85 24/85 43/85 54/84 49/84 35/84 20/84 5/76 3/48 0/14 
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